A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells
A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells
复制标题
DOI：
10.1016/j.canlet.2006.01.013
复制
发表时间：
2007-01-08
期刊：
影响因子：
9.7
通讯作者：
Ravid, Dana
中科院分区：
文献类型：
--
作者：
Liscovitch, Mordechai;Ravid, Dana
耐多药MCF-7乳腺腺癌细胞（最初命名为MCF-7/AdrR细胞，后来重新命名为NCI/ADR-RES）在过去二十年中成为一种重要且广泛使用的研究工具。然而，自1998年以来，这些细胞的真实身份一直存在疑问，此后一直存在争议。Sanger研究所和NCI分别进行了SNP和核型分析，揭示了NCI/ADR-RES细胞的起源。最近发表在网络上的这些分析结果表明，NCI/ADR-RES细胞来源于OVCAR-8卵巢腺癌细胞。NCI/ADR-RES细胞的病例突出了细胞系交叉污染和错误识别的广泛问题。幸运的是，这是一个容易处理的问题，可以通过谨慎的细胞基因分型和在细胞培养实践中采用一些简单的规则来避免。2006爱思唯尔爱尔兰有限公司版权所有。
Multidrug-resistant MCF-7 breast adenocarcinoma cells (originally named MCF-7/AdrR cells and later re-designated NCI/ADR-RES) have served as an important and widely used research tool during the last two decades. However, the real identity of these cells has been in doubt since 1998 and has since been debated. The origin of NCI/ADR-RES cells has now been revealed by SNP and karyotypic analyses, carried out at the Sanger Institute and the NCI, respectively. The results of these analyses, recently posted on the Web, show that NCI/ADR-RES cells are derived from OVCAR-8 ovarian adenocarcinoma cells. The case of NCI/ADR-RES cells highlights a wide-spread problem of cell line cross-contamination and misidentification. Fortunately, this is a tractable problem that can be avoided by scrupulous genotyping of cell stocks and adoption of a few simple rules in cell culture practice. (c) 2006 Elsevier Ireland Ltd. All rights reserved.